March 1, 1989European Heart Journal
The future of saphenous vein as a coronary artery bypass conduit
Population
Patients undergoing coronary artery bypass grafting using autologous saphenous vein
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May inform integrated CABG graft strategies; leaves open optimal component testing in prospective trials.
Key Points
- To review biological mechanisms mediating saphenous vein graft occlusion after coronary artery bypass grafting and identify targeted interventions to enhance long-term graft patency.
- Reviewed experimental and clinical evidence addressing platelet activation, endothelial damage, and smooth muscle cell proliferation in early and late vein graft failure.
- Analyzed pathophysiological overlaps between coronary vein graft occlusion and native atherogenesis.
- Identified that while platelet activation mediates early thrombotic graft occlusion, secondary pathways such as smooth muscle cell proliferation drive late occlusion.
- Proposed a multi-pronged intervention strategy including surgical endothelial preservation, antiplatelet agents preventing adhesion and aggregation, cholesterol reduction, and proliferation inhibitors like heparin.
Structured PICO
P
Population
Patients undergoing coronary artery bypass grafting using autologous saphenous vein
I
Intervention
Strategies to improve vein graft patency (including endothelial preservation, antiplatelet agents, risk factor reduction, and heparin)
O
Outcome
Vein graft patency/occlusion
Improving saphenous vein graft patency requires a multifaceted approach including endothelial preservation, advanced antiplatelet therapy, risk factor modification, and inhibition of smooth muscle cell proliferation.
Cite This Study
Angelini et al. (1989) studied this question.